NASH drug development strategy Challenge: A private biotech company with first in class, early lead compounds targeting a novel metabolic signaling protein engaged Alacrita’s NASH consultant to explore the best disease pathways for development. One potential disease target was non-alcoholic steatohepatitis (NASH) which is a large potential commercial opportunity. However, the company was concerned about the existing competition, and the expense and time required to compile the studies necessary for submission of an IND. Alacrita was engaged to evaluate competition in the space, required IND-enabling studies, and provide strategic advice on pursuing NASH as an indication for their novel target and compounds. Solution Utilizing internal staff and its expert pharma network, Alacrita approache

Join for free to read